Dotinor 0.5

Dotinor 0.5 (Dotinurad) is a medication primarily used for managing hyperuricemia in patients with gout. It belongs to the class of selective urate transporter 1 (URAT1) inhibitors. This drug works by inhibiting URAT1, reducing uric acid reabsorption in the kidneys, and promoting its excretion through the urine.

Indications

• Treatment of hyperuricemia in patients with gout.
• Management of conditions associated with elevated serum uric acid levels.

Mechanism of Action

Dotinurad selectively inhibits URAT1 in the renal tubular cells. By reducing the reabsorption of uric acid into the bloodstream, it increases uric acid excretion, thereby lowering serum uric acid levels effectively and consistently.

Dosage and Administration

• Recommended Dose: 0.5 mg once daily, or as prescribed by a healthcare professional.
• Administered orally, with or without food.

Key Benefits

• Effective in lowering serum uric acid levels.
• Well-tolerated with a favorable safety profile.
• Suitable for long-term management of hyperuricemia in gout patients.

Precautions and Warnings

• Not recommended for patients with severe renal impairment.
• Caution in patients with a history of hypersensitivity to Dotinurad or its components.
• Regular monitoring of serum uric acid levels and renal function is advised.

Side Effects

Common side effects may include:

• Dizziness
• Nausea
• Mild gastrointestinal discomfort
• Increased risk of kidney stones (rare)

Storage Instructions

• Store in a cool, dry place away from direct sunlight.
• Keep out of reach of children.